To further explore the effect of VCAM-1 on hypertension and vascular remodeling, we administered a VCAM-1 neutralizing antibody (0.1 and 0.2 mg/mouse/day) or IgG control to WT mice for 1 day and then administered Ang II (490 ng kg−1 min−1) or saline via continuous infusion for up to 14 days. Here, VCAM1 is linked to hypertensive disorder.